Shares of Adaptimmune Therapeutics PLC (NASDAQ:ADAP) have received an average rating of “Hold” from the eight ratings firms that are covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $15.50.
A number of equities research analysts have issued reports on the stock. Leerink Swann reissued an “outperform” rating and issued a $15.00 price target on shares of Adaptimmune Therapeutics PLC in a report on Friday. BidaskClub raised shares of Adaptimmune Therapeutics PLC from a “sell” rating to a “hold” rating in a report on Sunday, July 16th. Zacks Investment Research lowered shares of Adaptimmune Therapeutics PLC from a “buy” rating to a “hold” rating in a report on Monday, July 17th. Cowen and Company reissued a “buy” rating on shares of Adaptimmune Therapeutics PLC in a report on Tuesday, June 6th. Finally, ValuEngine raised shares of Adaptimmune Therapeutics PLC from a “strong sell” rating to a “sell” rating in a report on Thursday, July 20th.
TRADEMARK VIOLATION WARNING: “Adaptimmune Therapeutics PLC (ADAP) Given Average Rating of “Hold” by Analysts” was originally published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this news story on another site, it was stolen and republished in violation of US and international copyright & trademark laws. The correct version of this news story can be viewed at https://ledgergazette.com/2017/09/19/adaptimmune-therapeutics-plc-adap-given-average-rating-of-hold-by-analysts.html.
Institutional investors and hedge funds have recently made changes to their positions in the company. Raymond James Financial Services Advisors Inc. bought a new stake in shares of Adaptimmune Therapeutics PLC during the 1st quarter valued at about $120,000. KCG Holdings Inc. bought a new stake in shares of Adaptimmune Therapeutics PLC during the 1st quarter valued at about $133,000. Monashee Investment Management LLC bought a new stake in shares of Adaptimmune Therapeutics PLC during the 1st quarter valued at about $138,000. Paloma Partners Management Co bought a new stake in shares of Adaptimmune Therapeutics PLC during the 1st quarter valued at about $165,000. Finally, OxFORD Asset Management LLP bought a new stake in shares of Adaptimmune Therapeutics PLC during the 2nd quarter valued at about $156,000. 68.01% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Adaptimmune Therapeutics PLC (ADAP) traded down 3.95% during mid-day trading on Tuesday, hitting $8.50. 375,484 shares of the company traded hands. The stock’s market capitalization is $794.91 million. The firm’s 50 day moving average price is $5.70 and its 200-day moving average price is $5.18. Adaptimmune Therapeutics PLC has a 1-year low of $3.76 and a 1-year high of $8.95.
Adaptimmune Therapeutics PLC (NASDAQ:ADAP) last announced its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.24). The business had revenue of $3.52 million for the quarter, compared to analyst estimates of $5.43 million. Adaptimmune Therapeutics PLC had a negative net margin of 438.00% and a negative return on equity of 38.73%. On average, equities research analysts forecast that Adaptimmune Therapeutics PLC will post ($0.99) EPS for the current year.
About Adaptimmune Therapeutics PLC
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients.
Receive News & Ratings for Adaptimmune Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics PLC and related companies with MarketBeat.com's FREE daily email newsletter.